ArticleDrug safety2015
Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.
Article in Drug safety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Limited Evidence to Fully Determine the Implementation of Evidence-Based Practice by Healthcare Providers in Africa: A Systematic Review and Meta-Analysis.Journal of evidence-based medicine · 2025Pooled it
- Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.Thrombosis research · 2020Pooled it
- Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis.Drug safety · 2019Pooled it
- Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis.Drug safety · 2017Pooled it
- Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews.BMC medical informatics and decision making · 2017Pooled it
- Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review.European journal of clinical pharmacology · 2015Pooled it
- Impact of medication nonadherence and drug-drug interaction testing on the management of primary care patients with polypharmacy: a randomized controlled trial.BMC medicine · 2024Trial
- Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.Clinical pharmacokinetics · 2020Trial
- Assessment of Potential Drug-Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study.Drugs - real world outcomes · 2026Article
- SafeRx: A Canonical Pharmaceutical Knowledge Integration Framework for Multimodal Medication Safety.Bioengineering (Basel, Switzerland) · 2026Article
- Polypharmacy and Drug-Drug Interactions in Chronic Obstructive Pulmonary Disease: A Narrative Clinical Review.Pharmaceutics · 2026Review
- Screening for Potential Drug-Drug Interactions in Patients Receiving Anticoagulant Therapy: A Comparison of Three Drug Interaction Databases for Consistency in Severity Rating, Evidence Classification, and Clinical Management.Medicina (Kaunas, Lithuania) · 2026Article
- How to manage the overwhelming amount of database-detected interactions? A focus group meeting study on the management of database-detected risks of drug interactions.European journal of hospital pharmacy : science and practice · 2026Article
- Interactions Between Direct Oral Anticoagulants and Drugs Involving CYP-Enzymes and P-gp Transporters Detected by a Clinical Decision Support System: A Retrospective Cohort Study.Cardiovascular drugs and therapy · 2026Article
- Closing the loop: human-augmented, mechanistically enhanced AI for proactive management of drug-drug interactions.Frontiers in pharmacology · 2026Article
- Investigating the Quality of Mobile Apps for Drug-Drug Interaction Management Using the Mobile App Rating Scale and K-Means Clustering: Systematic Search of App Stores.JMIR mHealth and uHealth · 2025Article
- Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial.The oncologist · 2025Article
- medicX-KG: a knowledge graph for pharmacists' drug information needs.Journal of biomedical semantics · 2025Article
- A comparison of five different drug-drug interaction checkers for selective serotonin reuptake inhibitors.Frontiers in pharmacology · 2025Article
- Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review.Frontiers in pharmacology · 2025Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundHealthcare organizations, compendia, and drug knowledgebase vendors use varying methods to evaluate and synthesize evidence on drug-drug interactions (DDIs). This situation has a negative effect on electronic prescribing and medication information systems that warn clinicians of potentially harmful medication combinations.
objectiveThe aim of this study was to provide recommendations for systematic evaluation of evidence for DDIs from the scientific literature, drug product labeling, and regulatory documents.
methodsA conference series was conducted to develop a structured process to improve the quality of DDI alerting systems. Three expert workgroups were assembled to address the goals of the conference. The Evidence Workgroup consisted of 18 individuals with expertise in pharmacology, drug information, biomedical informatics, and clinical decision support. Workgroup members met via webinar 12 times from January 2013 to February 2014. Two in-person meetings were conducted in May and September 2013 to reach consensus on recommendations.
resultsWe developed expert consensus answers to the following three key questions. (i) What is the best approach to evaluate DDI evidence? (ii) What evidence is required for a DDI to be applicable to an entire class of drugs? (iii) How should a structured evaluation process be vetted and validated?
conclusionEvidence-based decision support for DDIs requires consistent application of transparent and systematic methods to evaluate the evidence. Drug compendia and clinical decision support systems in which these recommendations are implemented should be able to provide higher-quality information about DDIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.